Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash from Investing Activities came in at -$1.0 billion in Q1 2026, down 250.17% year-on-year from $692.6 million in Q1 2025, and up 76.81% quarter-over-quarter from -$4.5 billion in Q4 2025.
Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$1.0 billion for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$1.0 billion, down 250.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.3 billion (down 32.0% YoY), and the FY2025 annual result was -$23.6 billion, down 26.82% from the prior year.
- Cash from Investing Activities came in at -$1.0 billion for Q1 2026 at Johnson & Johnson, up from -$4.5 billion in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $3.3 billion in Q2 2023 to a low of -$18.3 billion in Q2 2025.
- The 5-year median for Cash from Investing Activities is -$1.3 billion (2024), against an average of -$3.7 billion.
- Across the five-year window, Cash from Investing Activities plunged 1864.32% in 2022 and surged 191.22% in 2023, its largest moves.
- Johnson & Johnson's Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then fell by 9.82% to -$1.3 billion in 2024, then sank by 239.77% to -$4.5 billion in 2025, then soared by 76.81% to -$1.0 billion in 2026.
- The last three Cash from Investing Activities figures came in at -$1.0 billion (Q1 2026), -$4.5 billion (Q4 2025), and -$542.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -1.98 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -1.04 Bn |
| Mar 29, 2026 | -1.04 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Sep 28, 2025 | -542.00 Mn |
| Sep 28, 2025 | -542.00 Mn |
| Jun 29, 2025 | -18.26 Bn |
| Jun 29, 2025 | -18.26 Bn |
| Mar 30, 2025 | -297.00 Mn |
| Mar 30, 2025 | -297.00 Mn |
| Dec 29, 2024 | -1.32 Bn |
| Dec 29, 2024 | -1.32 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Mar 31, 2024 | -464.00 Mn |
| Mar 31, 2024 | -464.00 Mn |
| Dec 31, 2023 | -1.20 Bn |
| Dec 31, 2023 | -1.20 Bn |